{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:07Z","timestamp":1740144187089,"version":"3.37.3"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008982","name":"Qatar National Research Fund","doi-asserted-by":"crossref","award":["QNRF NPRP Grant # 7-916-3-237"],"award-info":[{"award-number":["QNRF NPRP Grant # 7-916-3-237"]}],"id":[{"id":"10.13039\/100008982","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Scleromyxedema (rare cutaneous mucinosis), is characterized by the formation of lichenoid papules and presence of Serum monoclonal IgG in most cases, or all; after repeated testing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns<\/jats:title>\n            <jats:p>: The patient is a 51-year-old male presented with thick, disfiguring elephant-like erythematous skin folds over the forehead, papular shiny eruptions over ears and trunk and waxy erythematous papules over arms and hands without dysphagia or respiratory or neurologic symptoms<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis<\/jats:title>\n            <jats:p>: Skin biopsy from right arm was consistent with scleromyxedema. Serum cryoglobulin was reported negative. Complete blood count and routine blood biochemistry were normal. Thyroid function tests were normal. Serum protein electrophoresis and immunofixation showed monoclonal band of 14.5\u200ag\/L typed as IgG lambda.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions<\/jats:title>\n            <jats:p>: Our patient was refractory to lenalidomide however improved clinically on immunoglobulins infusions on monthly basis without change in the MGUS level.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes<\/jats:title>\n            <jats:p>: NGF analysis revealed approximately 0.25% Lambda monotypic plasma cells in the bone marrow expressing CD38, CD138, and CD27 with aberrant expression of CD56 and were negative for CD45, CD19, CD117, and CD81. We also detected 0.002% circulating plasma cells (PCs) in peripheral blood.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>: The immunophenotype of circulating tumor cells (CTCs) remain close to the malignant PCs phenotype in the BM. Hence, we report NGF approach as a novel diagnostic tool for highly sensitive MRD detection in plasma cell dyscrasias including scleromyxedema.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020726","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T16:40:30Z","timestamp":1593448830000},"page":"e20726","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of circulating myeloma tumor cells by next generation flowcytometry in scleromyxedema patient: a case report"],"prefix":"10.1097","volume":"99","author":[{"given":"Ruba Y.","family":"Taha","sequence":"first","affiliation":[{"name":"Hamad Medical Corporation, Hematology and Medical Oncology Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saba","family":"Hasan","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Hematology and Medical Oncology Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firyal","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporations, department and Laboratory Medicine and Pathology, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Chantran","sequence":"additional","affiliation":[{"name":"Department of Immunology, Hospital St Antoine, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesham El","family":"Sabah","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Hematology and Medical Oncology Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siveen","family":"Sivaraman","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporations, Interim Translational research Institute iTRI, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issam Al","family":"Bozom","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporations, department and Laboratory Medicine and Pathology, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad Al","family":"Sabbagh","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporations, department and Laboratory Medicine and Pathology, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Garderet","sequence":"additional","affiliation":[{"name":"Maladies du sang CHU de l\u2019AP-HP H\u00f4pital St-Antoine 184 rue du fg St-Antoine 75571 Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halima El","family":"Omri","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Hematology and Medical Oncology Department"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"key":"R1-20240214","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/joim.12590","article-title":"Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes","volume":"281","author":"Landgren","year":"2017","journal-title":"J Intern Med"},{"key":"R2-20240214","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","article-title":"Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival","volume":"26","author":"Lahuerta","year":"2008","journal-title":"J Clin Oncol"},{"key":"R3-20240214","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","article-title":"Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials","volume":"31","author":"Sonneveld","year":"2013","journal-title":"J Clin Oncol"},{"key":"R4-20240214","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/leu.2012.160","article-title":"Improvement in long-term outcomes with successive total therapy trials for multiple myeloma: are patients now being cured?","volume":"27","author":"Usmani","year":"2013","journal-title":"Leukemia"},{"key":"R5-20240214","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"key":"R6-20240214","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1586\/17474086.2014.864230","article-title":"Initial treatment of transplantineligible patients in multiple myeloma","volume":"7","author":"Mateos","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"R7-20240214","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"Rollig","year":"2015","journal-title":"Lancet"},{"key":"R8-20240214","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.blre.2015.06.001","article-title":"Treatment for patients with newly diagnosed multiple myeloma in 2015","volume":"29","author":"Mateos","year":"2015","journal-title":"Blood Rev"},{"key":"R9-20240214","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood"},{"key":"R10-20240214","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1200\/JCO.2010.33.1967","article-title":"Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma","volume":"29","author":"Paiva","year":"2011","journal-title":"J Clin Oncol"},{"key":"R11-20240214","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V124.21.3390.3390","article-title":"Clinical significance of sensitive Flow-MRD monitoring in elderly multiple myeloma patients on the Pethema\/GEM2010MAS65 Trial","volume":"124","author":"Paiva","year":"2014","journal-title":"Blood"},{"key":"R12-20240214","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"key":"R13-20240214","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2001-12-0297","article-title":"Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation","volume":"100","author":"Rawstron","year":"2002","journal-title":"Blood"},{"key":"R14-20240214","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","article-title":"Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction","volume":"125","author":"Rawstron","year":"2015","journal-title":"Blood"},{"key":"R15-20240214","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1038\/bcj.2013.33","article-title":"A single tube multiparameter sevencolour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma","volume":"3","author":"Robillard","year":"2013","journal-title":"Blood Cancer J"},{"issue":"(8 Pt 2)","key":"R16-20240214","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/clinchem\/46.8.1221","article-title":"Flow cytometry: principles and clinical applications in hematology","volume":"46","author":"Brown","year":"2000","journal-title":"Clin Chem"},{"key":"R17-20240214","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"R18-20240214","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"key":"R19-20240214","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J"},{"key":"R20-20240214","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000452319","article-title":"Scleromyxedema without paraproteinemia: treatment with thalidomide and prednisolone","volume":"8","author":"Saniee","year":"2016","journal-title":"Case Rep Dermatol"},{"key":"R21-20240214","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1067\/mjd.2001.111630","article-title":"Updated classification of popular mucinosis, lichen myxodematosus andscleromyxedema","volume":"44","author":"Rongioletti","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"R22-20240214","doi-asserted-by":"crossref","first-page":"592","DOI":"10.4103\/0378-6323.69096","article-title":"Generalized popular sclerodermoid eruption: scleromyxedema","volume":"76","author":"Serdar","year":"2010","journal-title":"Indian J Dermatol Venerol Leprol"},{"key":"R23-20240214","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4103\/0378-6323.41372","article-title":"Suspected cardiac toxcicity to intravenous immunoglobulin used for treatment of scleromyxedema","volume":"74","author":"Binitha","year":"2008","journal-title":"Indian J Dermatol Leprol"},{"key":"R24-20240214","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/0019-5154.53183","article-title":"Arndt Gottron Scleromyxedema: successful response to treatment with steroid minipulse and methotrexate","volume":"54","author":"Mehta","year":"2009","journal-title":"Indian J Dermatol"},{"key":"R25-20240214","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/0012-1606(79)90042-3","article-title":"Presence of mast cell precursors in fetal liver of mice","volume":"70","author":"Kitamura","year":"1979","journal-title":"Dev Biol"},{"key":"R26-20240214","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"R27-20240214","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaad.2013.01.007","article-title":"Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients","volume":"69","author":"Rongioletti","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R28-20240214","first-page":"45","article-title":"Scleromyxedema: a case clinically and histologically responsive to intravenous immunoglobulin","volume":"7","author":"Caudill","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"R30-20240214","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jaad.2008.11.013","article-title":"Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin","volume":"60","author":"Rey","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R31-20240214","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ajh.22131","article-title":"Scleromyxedema and dermato-neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib","volume":"86","author":"Fett","year":"2011","journal-title":"Am J Hematol"},{"key":"R32-20240214","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0140-6736(16)31401-5","article-title":"Scleromyxoedema","volume":"389","author":"Van Leersum","year":"2017","journal-title":"Lancet"},{"key":"R33-20240214","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5114\/pdia.2013.34165","article-title":"Scleromyxedema: a rare disorder and its treatment difficulties","volume":"30","author":"Koronowska","year":"2013","journal-title":"Postepy Dermatol Alergol"},{"key":"R34-20240214","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/21678707.2018.1466700","article-title":"Advances in understanding and treatment of scleromyxedema","volume":"6","author":"Atzori","year":"2018","journal-title":"Expert Opin Orphan Drugs"},{"key":"R35-20240214","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jdcr.2017.04.005","article-title":"Paraneoplastic atypical scleromyxedema with advanced gastric cancer","volume":"3","author":"Oh","year":"2017","journal-title":"JAAD Case Rep"},{"key":"R36-20240214","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/0019-5154.174204","article-title":"Scleromyxedema clinically resembling to scleroderma","volume":"61","author":"Aoki","year":"2016","journal-title":"Indian J Dermatol"},{"key":"R37-20240214","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1365-4362.1989.tb02439.x","article-title":"Scleromyxedema associated with non-Hodgkin lymphoma","volume":"28","author":"Gim\u00e9nez Garcia","year":"1989","journal-title":"Int J Dermatol"},{"key":"R38-20240214","first-page":"219","article-title":"Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema","volume":"39","author":"Helm","year":"1987","journal-title":"Cutis"},{"key":"R39-20240214","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"R40-20240214","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"R41-20240214","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2013-06-510453","article-title":"Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile","volume":"122","author":"Paiva","year":"2013","journal-title":"Blood"},{"key":"R42-20240214","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/cyto.b.21606","article-title":"Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma","volume":"94","author":"Bae","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"key":"R43-20240214","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies","volume":"125","author":"van Dongen","year":"2015","journal-title":"Blood"},{"key":"R44-20240214","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood-2013-05-506170","article-title":"Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity","volume":"122","author":"Flanders","year":"2013","journal-title":"Blood"},{"key":"R45-20240214","doi-asserted-by":"crossref","first-page":"E502","DOI":"10.1002\/ajh.24540","article-title":"Myeloma minimal residual disease testing in the United States: evidence of improved standardization","volume":"91","author":"Salem","year":"2016","journal-title":"Am J Hematol"},{"key":"R46-20240214","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cyto.b.21249","article-title":"Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition","volume":"90","author":"Stetler-Stevenson","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"R47-20240214","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"key":"R48-20240214","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cyto.b.21228","article-title":"Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting","volume":"90","author":"Arroz","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"R49-20240214","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"R50-20240214","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/blood.V99.5.1853","article-title":"Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome","volume":"99","author":"San Miguel","year":"2002","journal-title":"Blood"},{"key":"R51-20240214","article-title":"Scleredema and Scleromyxedema","author":"Weening","year":"2008","journal-title":"Fitzpatrick's Dermatology in General Medicine"},{"key":"R52-20240214","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2340\/00015555-0731","article-title":"Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema","volume":"89","author":"Laimer","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"R53-20240214","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.semarthrit.2007.10.015","article-title":"Intravenous gammaglobulin and thalidomide may be an eff ective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature","volume":"38","author":"Efthimiou","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"R54-20240214","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-540-29316-3_87","article-title":"Mucinoses","author":"Meigel","year":"2009","journal-title":"Braun-Falco's Dermatology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T16:08:57Z","timestamp":1707926937000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":53,"journal-issue":{"issue":"27","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020726","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,7,2]]}}}